Supply Chain

Target Corp. on Wednesday introduced new guidelines surrounding use of chemicals in products.

Danish drugmaker Lundbeck is working with Ossianix, a Philadelphia-based biotechnology firm, to develop new drugs that can more effectively reach the brain to treat Alzheimer's and other diseases, reports Reuters.

Mylan CEO Heather Bresch spoke with "CBS This Morning" co-host Norah O'Donnell in her first interview since testifying before Congress on the high price of EpiPens, reports CBS News.

Barr Laboratories, a subsidiary of Teva Pharmaceutical Industries, will pay $225 million as part of an antitrust class-action lawsuit settlement to resolve allegations it kept a generic version of Bayer's antibiotic Cipro off the market, reports Reuters.

At least 17 pharmaceutical companies saw stock prices tumble after President Donald Trump gave a speech earlier this month in which he lambasted the industry.

White House Press Secretary Sean Spicer on Thursday suggested the U.S. could impose a 20 percent tax on Mexican goods as one way to pay for President Trump's proposed border wall, reports CNBC.

A nationwide shortage of available warehouse space is gradually resolving, according to The Wall Street Journal.

Although Novartis earned approval from the Food and Drug Administration for its biosimilar drug Erelzi, the Swiss drugmaker said it will not hit the market before 2018 due to a patent dispute with Thousand Oaks, Calif.-based Amgen, reports Reuters.

Biogen updated the label for its best-selling oral multiple sclerosis drug Tecfidera to include a warning about risk of liver injury that can occur when taking the drug, reports Reuters.

Here are seven articles published by Becker's Hospital Review in the past week that offer insight on the pharmaceutical industry, top priorities for supply chain leaders in 2017 and more.